In a statement made by Türk İlaç to the Moscow Press Office, it was noted that the company and Moscow-based Chromis decided to cooperate on the production and sale of the drug Avifavir, developed for the treatment of Kovid-19, in Turkey.
Regarding this cooperation, it was stated that the parties 'signed a framework agreement in which the main commercial and legal lines were determined'.
A framework agreement has been signed between Chromis LLC Company located in Russia and TURK İlaç Ve Serum Sanayi A.Ş, in which the main commercial and legal lines are determined regarding the sale and production of the drug named AVIFAVIR with favipiravir active ingredient used in the treatment of coronavirus Kovid-19.
In clinical studies, the drug, which was found to be at least 80 percent effective, accelerates the healing process of patients and destroys the effects of the virus. While the effect of the virus disappears in 9 days with standard treatment, this period is reduced to 4 days with the use of Avifavir.